Abstract
Birçok yayınlanmış vaka sunumlarında gebeliğin ilk trimestirinde olmasa da 3. Trimestri süresince anjiyotensin II reseptör antagonistlerinin kullanımının fetotoksik olduğu bildirilmiştir. İyi kontrollü kronik hipertansif ve valsartan 160 mg kullanan 40 yaşında bayan bir hasta gebeliğinin 25. Haftasına kadar bu ilacı kullanıyordu. Sonrasında valsartan kesilmiş ve alfa-metildopa 1000 mg başlanmış ve dozu kan basıncı kontrolüne kadar titre edilmiştir. Hastada yapılan yapılan obstetrik ultrasonografide fetal ve amniyotik anormallik saptanmamıştır. Doğum sonrası izlemde ise bebekte neonatal tıbbi bir problem izlenmedi. Bebeğin büyüme parametrelerinde ve renal fonksiyonlarında bir anormallik gözlenmedi. Sonuç olarak, bizim vakamızda 1. ve 2. Trimester süresince anjiotensin II reseptör antogonisti kullanan şanslı bir gebe olgusunu rapor ettik
Keywords
References
- Alwan S, Polifka JE, Friedman JM. Angiotension II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005; 73(2):123-130.
- Sánchez SI, Seltzer AM, Fuentes LB, et al. Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. Eur J Pharmacol. 2008 24;588(1):114-123.
- Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antogonist: case report and follow up after birth. Ann Pharmacother. 2005;39(1):157-161.
- Spence SG, Allen HL, Cukierski MA, et al. Defining the susceptible period of developmental toxicity for the AT1-selectiveangiotensin II receptor antagonist losartan in rats. Teratology. 1995;51(6): 367–382.
- Chung NA, Lip GYH, Beevers M, et al. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 2001; 357(9268):1620-1621.
- Markham A, Goa KL. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54(2): 299–311.
- Roger N, Popovic I, Madelenat P, et al. Fetal toxicity of angiotensin-II-receptor inhibitors: Case report. Gynecol Obstet Ferti.l 2007,35(6):556-560.
- Berkane N, Carlier P, Verstraete L, et al. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol. 2004;70(8):547-549.
- Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother. 2001; 35(7-8): 859–861.
Abstract
Keywords
References
- Alwan S, Polifka JE, Friedman JM. Angiotension II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005; 73(2):123-130.
- Sánchez SI, Seltzer AM, Fuentes LB, et al. Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. Eur J Pharmacol. 2008 24;588(1):114-123.
- Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antogonist: case report and follow up after birth. Ann Pharmacother. 2005;39(1):157-161.
- Spence SG, Allen HL, Cukierski MA, et al. Defining the susceptible period of developmental toxicity for the AT1-selectiveangiotensin II receptor antagonist losartan in rats. Teratology. 1995;51(6): 367–382.
- Chung NA, Lip GYH, Beevers M, et al. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 2001; 357(9268):1620-1621.
- Markham A, Goa KL. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54(2): 299–311.
- Roger N, Popovic I, Madelenat P, et al. Fetal toxicity of angiotensin-II-receptor inhibitors: Case report. Gynecol Obstet Ferti.l 2007,35(6):556-560.
- Berkane N, Carlier P, Verstraete L, et al. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol. 2004;70(8):547-549.
- Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother. 2001; 35(7-8): 859–861.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | August 1, 2012 |
| Published in Issue | Year 2012 Volume: 4 Issue: 2 |